Skip to main content
I

IMAGION BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · IBX ISIN · AU000000IBX6 ASX Professional, scientific and technical activities
Filings indexed 653 across all filing types
Latest filing 2023-08-24 Regulatory Filings
Country AU Australia
Listing ASX IBX

About IMAGION BIOSYSTEMS LIMITED

https://imagionbiosystems.com/

Imagion Biosystems Limited is a medical technology company specializing in the development of advanced diagnostic imaging solutions. The company's proprietary MagSense technology utilizes superparamagnetic iron oxide nanoparticles to detect specific cancer cells non-invasively. By functionalizing these nanoparticles with targeting antibodies, the system can identify the presence and location of malignancies, such as HER2-positive breast cancer, using highly sensitive magnetic sensors. This approach aims to provide a safer, more accurate alternative to traditional biopsy and imaging methods by eliminating the need for ionizing radiation or radioactive tracers. The technology is designed to improve clinical decision-making through earlier detection and better staging of diseases, ultimately enhancing patient outcomes in oncology.

Recent filings

Filing Released Lang Actions
Convertible Note Investment 2 pages 301.8KB
Regulatory Filings
2023-08-24 English
Notification regarding unquoted securities - IBX 7 pages 29.0KB
Regulatory Filings
2023-08-24 English
Notification regarding unquoted securities - IBX 9 pages 34.0KB
Regulatory Filings
2023-08-24 English
Cleansing Statement under Section 708A(12C)(e) 11 pages 450.2KB
Regulatory Filings
2023-08-24 English
Proposed issue of securities - IBX 6 pages 31.0KB
Regulatory Filings
2023-08-23 English
MOU to develop early pancreatic cancer diagnosis platform 3 pages 365.2KB
Regulatory Filings
2023-08-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.